Closed-Loop Insulin Delivery Systems for People with Type 1 Diabetes and Chronic Very Poor Metabolic Control: It Works and Is Safe!

被引：4

作者：

Deepchand, Sonia ^{[1
]}

Balla, Vanessa ^{[1
]}

Eroukhmanoff, Juliette ^{[1
]}

Sall, Khadijatou Ly ^{[1
]}

Romain, Benedicte ^{[1
]}

Lejeune, Marie ^{[1
]}

Penfornis, Alfred ^{[1
,2
]}

Amadou, Coralie ^{[1
,2
,3
]}

机构：

[1] Sud Francilien Hosp, Diabet Dept, Corbeil Essonnes, France

[2] Paris Saclay Univ, Med Sch, Paris, France

[3] Sud Francilien Hosp, Diabet Dept, F-91190 Corbeil Essonnes, France

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2024年 / 26卷 / 02期

关键词：

Closed-loop systems; Continuous glucose monitoring; Type; 1; diabetes; Poor metabolic control; GLYCEMIC CONTROL; RETINOPATHY;

D O I：

10.1089/dia.2023.0379

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To evaluate the percentage of patients with type 1 diabetes (T1D) and very poor metabolic control who would agree to be treated with a hybrid closed-loop (HCL) insulin delivery system, and to assess metabolic improvement and safety. In a single center, we identified all patients aged >18 years with hemoglobin A1c (HbA1c) >11% (97 mmol/mol) before HCL treatment. We collected metabolic control and safety data up to 1 year post-HCL in those who accepted HCL after it was proposed to them. We identified 65 patients eligible for the study, 32 (50%) already used, or accepted to start using HCL. Patients were aged 18-49 years; mean(+/- standard deviation) baseline HbA1c was 12.5(+/- 1.8)% (113 +/- 20 mmol/mol). After 1 year, 25 patients (78%) were still using HCL and their mean HbA1c decreased to 9.4(+/- 1.9)% (79 mmol/mol) (P < 0.001). The rate of acute metabolic events was similar during the year of follow-up to the rate in the 3 years before HCL initiation. HCL systems should be considered in patients with T1D and very poor metabolic control.

引用

页码：125 / 129

页数：5

共 13 条

[1] Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes [J].

Akturk, Halis Kaan ;

Giordano, Dominique ;

Champakanath, Anagha ;

Brackett, Scott ;

Garg, Satish ;

Snell-Bergeon, Janet .

DIABETES OBESITY & METABOLISM, 2020, 22 (04) :583-589

[2] Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up [J].

Amadou, Coralie ;

Franc, Sylvia ;

Benhamou, Pierre-Yves ;

Lablanche, Sandrine ;

Huneker, Erik ;

Charpentier, Guillaume ;

Penfornis, Alfred .

DIABETES CARE, 2021, 44 (03) :844-846

[3] 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022 [J].

American Diabetes Association Professional Practice Committee .

DIABETES CARE, 2022, 45 :S83-S96

[4] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range [J].

Battelino, Tadej ;

Danne, Thomas ;

Bergenstal, Richard M. ;

Amiel, Stephanie A. ;

Beck, Roy ;

Biester, Torben ;

Bosi, Emanuele ;

Buckingham, Bruce A. ;

Cefalu, William T. ;

Close, Kelly L. ;

Cobelli, Claudio ;

Dassau, Eyal ;

DeVries, J. Hans ;

Donaghue, Kim C. ;

Dovc, Klemen ;

Doyle, Francis J. ;

Garg, Satish ;

Grunberger, George ;

Heller, Simon ;

Heinemann, Lutz ;

Hirsch, Irl B. ;

Hovorka, Roman ;

Jia, Weiping ;

Kordonouri, Olga ;

Kovatchev, Boris ;

Kowalski, Aaron ;

Laffel, Lori ;

Levine, Brian ;

Mayorov, Alexander ;

Mathieu, Chantal ;

Murphy, Helen R. ;

Nimri, Revital ;

Norgaard, Kirsten ;

Parkin, Christopher G. ;

Renard, Eric ;

Rodbard, David ;

Saboo, Banshi ;

Schatz, Desmond ;

Stoner, Keaton ;

Urakami, Tatsuiko ;

Weinzimer, Stuart A. ;

Phillip, Moshe .

DIABETES CARE, 2019, 42 (08) :1593-1603

[5] Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections [J].

Boucsein, Alisa ;

Watson, Antony S. ;

Frewen, Carla M. ;

Sanders, Olivia J. ;

Haszard, Jillian J. ;

Jones, Shirley D. ;

Milford-Hughes, Philippa J. ;

de Bock, Martin I. ;

Wheeler, Benjamin J. .

DIABETES CARE, 2023, 46 (03) :628-632

[6] One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology [J].

Breton, Marc D. ;

Kovatchev, Boris P. .

DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (09) :601-608

[7] Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users [J].

Da Silva, Julien ;

Lepore, Giuseppe ;

Battelino, Tadej ;

Arrieta, Arcelia ;

Castaneda, Javier ;

Grossman, Benyamin ;

Shin, John ;

Cohen, Ohad .

DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (02) :113-119

[8] LONG-TERM GLYCEMIC CONTROL HAS A NONLINEAR ASSOCIATION TO THE FREQUENCY OF BACKGROUND RETINOPATHY IN ADOLESCENTS WITH DIABETES - FOLLOW-UP OF THE BERLIN RETINOPATHY STUDY [J].

DANNE, T ;

WEBER, B ;

HARTMANN, R ;

ENDERS, I ;

BURGER, W ;

HOVENER, G .

DIABETES CARE, 1994, 17 (12) :1390-1396

[9] Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes [J].

Feldman-Billard, S. ;

Larger, E. ;

Massin, P. .

DIABETES & METABOLISM, 2018, 44 (01) :4-14

[10] Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations [J].

Forlenza, Gregory P. ;

Carlson, Anders L. ;

Galindo, Rodolfo J. ;

Kruger, Davida F. ;

Levy, Carol J. ;

McGill, Janet B. ;

Umpierrez, Guillermo ;

Aleppo, Grazia .

DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (11) :814-823

← 1 2 →